2017 ASM/ESCMID Program Committee Disclosures

Helen W. Boucher, MD, FACP, FIDSA
Tufts Medical Center, Boston, MA

Marco Cavalieri, PhD
European Medicines Agency (EMA), Canary Wharf, London
M. Cavalieri, None

Edward Cox, MD, MPH
US Food and Drug Administration, Silver Spring, MD
E. Cox, None

George L. Drusano, MD
University of Florida, Orlando, FL
G. Drusano, Grants/Research Support: Roche; Motif Biosciences; Spero Therapeutics NIAID x 3 Consultant: Roche; Achaogen; Spero Therapeutics; F2G; NIAID; GARDP

David C. Hooper, MD
Massachusetts General Hospital, Boston, MA
D. C. Hooper, None

William Hope, BMBS, FRACP, FRCPA, PhD
University of Liverpool, Liverpool, United Kingdom
W. Hope, F2G Role(s): Grant Investigator, Scientific Advisor (Review Panel or Advisory Committee). Amplyx Role(s): Grant Investigator, Scientific Advisor (Review Panel or Advisory Committee). Basilea Role(s): Scientific Advisor (Review Panel or Advisory Committee). AiCuris Role(s): Grant Investigator. Spero Therapeutics Role(s): Grant Investigator. Auspherix Role(s): Scientific Advisor (Review Panel or Advisory Committee)

Gunnar O. Kahlmeter, MD
University of Lund, Växjö, Sweden
G.O. Kahlmeter, Thermofisher Scientific (Oxoid Ltd) Role(s): Consultant, Research Relationship.

Alasdair, MacGowan
North Bristol NHS Trust. Bristol, United Kingdom
A. MacGowan, Grants/Research Support: Bayer Healthcare, Achaogen, Merck, Paratek, VenatoRx, EU IMI, EU FP7, NIHR RfPB, Newton Fund

John Rex, MD
F2G, Ltd., CARB-X, Advent Life Sciences LLP, Manchester, United Kingdom
J. Rex, Consultant: Consulting fees from: Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Ganagen, Ltd. Stock Shareholder: AstraZeneca Pharmaceuticals; F2G, Ltd; Adenium Biotech ApS; Advent Life Sciences; Marolide Pharmaceuticals; Bugworks Research, Inc. Other Financial or Material Support: Chief Strategy Officer, CARB-X; Chief Medical Officer & Director, F2G, Ltd; Non-Executive
Keith A. Rodvold, Pharm.D., FCCP, FIDSA
University of Illinois at Chicago, Chicago, Ill
**K.A. Rodvold, Paratek Role(s):** Consultant, Scientific Advisor (Review Panel or Advisory Committee). **Merck Role(s):** Speaker's Bureau. **TheravanceRole(s):** Grant Investigator, Scientific Advisor (Review Panel or Advisory Committee). **ZavanteRole(s):** Consultant, Scientific Advisor (Review Panel or Advisory Committee). **Spero TherapeuticsRole(s):** Scientific Advisor (Review Panel or Advisory Committee). **AllerganRole(s):** Grant Investigator. **Bayer Role(s):** Scientific Advisor (Review Panel or Advisory Committee). **JanssenRole(s):** Other, Safety Monitoring Board.

Michael Sharland, MD
St. George’s Hospital, London, United Kingdom
**M. Sharland, The Paediatric Infectious Diseases Research Group (PIDRG) and St. George’s Vaccine Institute receive funding from GSK, Pfizer and Cubist pharmaceuticals to conduct investigator led research Role(s):** Self, N. Other.

Judith N. Steenbergen, PhD
Paratek Pharmaceuticals, King of Prussia, PA
**J.N. Steenbergen, Consultant:** Advisor to USCAST, CLSI Reviewer **Stock Shareholder:** Paratek Pharmaceuticals **Stock owner Other Financial or Material Support:** Current employee of Paratek Pharmaceuticals, Former employee of Merck (formerly Cubist), Former consultant for Tetraphase, Former consultant for ICPD, **Spouse:** Partner in a Urology Practice